GSK's Pre-Pandemic Vaccine Wins EU Marketing Approval
Posted on: Tuesday, 20 May 2008, 09:01 CDT
GlaxoSmithKline has announced that the European Commission has granted a marketing authorization for its H5N1 adjuvanted pre-pandemic vaccine, Prepandrix, in all 27 EU member states.
GSK's pre-pandemic H5N1 vaccine is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen that is long-lasting and active against a broad range of H5N1 strains.
GSK is said to be the first company to obtain a European license for a pre-pandemic vaccine, thereby offering European governments the potential for protecting their population in advance or at the onset of an officially declared influenza pandemic.
A pre-pandemic vaccine is produced in advance of a pandemic. Such a vaccine is based on the currently circulating avian H5N1 influenza virus likely to cause a pandemic and has the ability to raise immune protection against potential drift H5N1 strains.
Source: Datamonitor
Related Articles
- Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
- Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
- Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
- Sanofi Pasteur Signs Contract With U.S. Government for Stockpile of New Type of H5N1 Pre-Pandemic Vaccine
- Baxter Announces Safety and Immunogenicity Results From Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
- Baxter Initiates Clinical Study With Cell-Based Candidate H5N1 Pandemic Vaccine
- Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of Its Proprietary Avian Influenza Vaccine (H5N1)
- Sinovac Biotech Ltd. Begins Pandemic Flu (H5N1) Vaccine Clinical Trials
- Sanofi Pasteur Announces Preliminary Trial Results for a First H5N1 Pre-Pandemic Influenza Vaccine Candidate With an Adjuvant
 |
 |
User Comments (0)
RSS Feeds